This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miotto, P.
Right arrow Articles by Migliori, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miotto, P.
Right arrow Articles by Migliori, G. B.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2008, p. 393-394, Vol. 46, No. 1
0095-1137/08/$08.00+0     doi:10.1128/JCM.01066-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Genotype MTBDRplus: a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis{triangledown}


arrow
LETTER
 
In a previous publication (1), we evaluated the Genotype MTBDR (GT-MTBDR; Hain Lifescience, Nehren, Germany) assay as a rapid diagnostic tool for multidrug resistance (MDR) detection in Mycobacterium tuberculosis isolates and clinical specimens. The main limitation of the test was the low sensitivity for isoniazid resistance detection (70%), due to the targeting of only one (katG) of the genes involved (2). Furthermore, the test performance on clinical specimens was suboptimal because of the lack of a clear hybridization signal (unpublished data).

Recently, a new version of the test, the Genotype MTBDRplus (GT-MTBDRplus) assay, has been developed in order to improve the assay's sensitivity for isoniazid resistance and direct detection of drug resistance in clinical specimens. It targets all the genes included in the previous test with the addition of codons 505 to 510 in the hot-spot region of rpoB, to improve the detection of rifampin resistance, and the promoter region of the inhA gene (nucleotides –8, –15, and –16) for isoniazid resistance.

We tested with the GT-MTBDRplus assay 173 isoniazid-resistant isolates (Table 1) and 78 clinical specimens (Fig. 1) that had been previously analyzed with the GT-MTBDR version and compared the results with those of sequence analysis. DNA extraction from isolates and clinical specimens was performed as previously described (1).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Detection of isoniazid resistance in clinical isolates by the G-MTBDR and the G-MTBDRplus assays compared with sequencing data


Figure 1
View larger version (30K):
[in this window]
[in a new window]

  		FIG. 1. Comparison of the performance of the Genotype MTBDR assay with the Genotype MTBDRplus assay on clinical specimens. "Double pattern" refers to samples showing mutated and wild-type patterns simultaneously. DST, drug susceptibility testing; INH-R, isoniazid resistance.

The use of the GT-MTBDRplus assay allowed the correct identification of an additional 11.6% (20/173) of isoniazid-resistant strains compared to the results with the GT-MTBDR, with a specificity of 100%. In one sample, none of the tests allowed the detection of the katG gene due to the presence of several mutations in the same gene, as confirmed by the sequence analysis. Both the assays were interpreted as indeterminate for the katG analysis.

The two tests were also evaluated side by side (Fig. 1) on a panel of 78 respiratory samples that were positive by M. tuberculosis Direct test (MTD; bioMerieux, Marcy l'Etoile, France). Among the 78 clinical specimens analyzed, 31 were smear negative (25 fully susceptible, 4 isoniazid resistant, and 2 MDR) and 47 smear positive (41 fully susceptible, 5 isoniazid resistant, and 1 MDR). With the GT-MTBDR assay, we obtained a valid test for 18/31 (58.1%) smear-negative and 45/47 (95.7%) smear-positive samples and an indeterminate result defined as absence of positive amplification control in 15 cases (13 smear negative, 2 smear positive). In 12 cases (6 smear negative, 6 smear positive), despite the presence of a positive amplification control, the interpretation of the test was difficult due to the faint staining of some hybridization bands. The number of valid tests obtained by the new assay was 100% (47/47) for smear-positive and 70.9% (22/31) for smear-negative samples, with no ambiguity in the hybridization pattern. With smear-negative samples, the GT-MTBDRplus assay allowed the reduction of indeterminate results from 41.9% to 29.0% and improved the concordance rate with culture-based drug susceptibility testing from 29.0% to 64.5%. With the smear-positive clinical specimens, the GT-MTBDRplus assay increased the rate of concordance with the drug susceptibility testing results from 72.3% to 91.5%, without any indeterminate results. Results for all of the four samples showing simultaneously mutated and wild-type patterns with the first version of the assay were confirmed by the GT-MTBDRplus assay (Fig. 1).

The increased sensitivity of GT-MTBDRplus is due to the introduction of new targeted genes for isoniazid resistance coupled with better primer and probe design, allowing improved sensitivity with direct clinical specimens to provide rapid direct detection of drug resistance, essential to improve case management and, consequently, tuberculosis control.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 31 October 2007. Back


arrow
REFERENCES
 
    1
  1. Miotto, P., F. Piana, V. Penati, F. Canducci, G. B. Migliori, and D. M. Cirillo. 2006. Use of the Genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J. Clin. Microbiol. 44:2485-2491.[Abstract/Free Full Text]
    2. 2
  2. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29.[CrossRef][Medline]
Paolo Miotto
Federica Piana
Daniela Maria Cirillo*
Emerging Bacterial Pathogens Unit
San Raffaele Scientific Institute
Via Stamira d'Ancona 20
20127 Milan, Italy

Giovanni Battista Migliori
WHO Collaborating Centre for TB and Lung Diseases
Fondazione S. Maugeri
Via Roncaccio 16
21049 Tradate, Italy

* Phone: 39 02 26437947, Fax: 39 02 26437989, E-mail: cirillo.daniela{at}hsr.it

Journal of Clinical Microbiology, January 2008, p. 393-394, Vol. 46, No. 1
0095-1137/08/$08.00+0     doi:10.1128/JCM.01066-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hauck, Y., Fabre, M., Vergnaud, G., Soler, C., Pourcel, C. (2009). Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother 64: 259-262 [Abstract] [Full Text]  
  • Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C., Bottger, E. C. (2009). Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis by Use of MGIT 960 and EpiCenter Instrumentation. J. Clin. Microbiol. 47: 1773-1780 [Abstract] [Full Text]  
  • Springer, B., Calligaris-Maibach, R. C., Ritter, C., Bottger, E. C. (2008). Tuberculosis Drug Resistance in an Area of Low Endemicity in 2004 to 2006: Semiquantitative Drug Susceptibility Testing and Genotyping. J. Clin. Microbiol. 46: 4064-4067 [Abstract] [Full Text]  
  • Ling, D. I., Zwerling, A. A., Pai, M. (2008). GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174 [Abstract] [Full Text]  
  • Lacoma, A., Garcia-Sierra, N., Prat, C., Ruiz-Manzano, J., Haba, L., Roses, S., Maldonado, J., Dominguez, J. (2008). GenoType MTBDRplus Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical Samples. J. Clin. Microbiol. 46: 3660-3667 [Abstract] [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miotto, P.
Right arrow Articles by Migliori, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miotto, P.
Right arrow Articles by Migliori, G. B.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»